Active Biotech AB
The answer first
Does Active Biotech beat the market?
No, Active Biotech has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 8% of Nordic stocks
- Quality67
- Value3
- Trend6
No. 169 of 195 in healthcare
Max for seven days
Follow Active Biotech with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Active Biotech
Your first answer is free, no account needed.
Do you own Active Biotech, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Active Biotech and a few more. Free, no card.
Super Stock+45.9%In short
- Active Biotech has fallen 43.1% over the past year, including dividends.
- Overall, Active Biotech ranks better than 8% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 92.1%. The price is 100.0% below its peak now.
What do analysts think of Active Biotech?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 8% of Nordic stocks.
No. 169 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 93 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.06
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−124.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 176 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.1
- P/SPrice divided by sales954.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 171 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−34.4%
- 6 months−51.3%
- 9 months−9.7%
- 12 months−43.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Active Biotech
Active Biotech AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 5 employees.
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors.


See the full analysis of Active Biotech.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card